Patents by Inventor Massimo M. Trucco

Massimo M. Trucco has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MICROSPHERE-BASED DELIVERY AND EX VIVO MANIPULATION OF DENDRITIC CELLS FOR AUTOIMMUNE THERAPIES
    Publication number: 20210401884
    Abstract: The present invention relates to tolerogenic mammalian dendritic cells (iDCs) and methods for the production of tolerogenic DCs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects. Enhanced tolerogenicity in a host can be useful for treating inflammatory and autoimmune related diseases, such as type 1 diabetes.
    Type: Application
    Filed: February 3, 2021
    Publication date: December 30, 2021
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Nick Giannoukakis, Massimo M. Trucco
  • Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies
    Patent number: 10940164
    Abstract: The present invention relates to tolerogenic mammalian dendritic cells (iDCs) and methods for the production of tolerogenic DCs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects. Enhanced tolerogenicity in a host can be useful for treating inflammatory and autoimmune related diseases, such as type 1 diabetes.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: March 9, 2021
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Nick Giannoukakis, Massimo M. Trucco
  • MICROSPHERE-BASED DELIVERY AND EX VIVO MANIPULATION OF DENDRITIC CELLS FOR AUTOIMMUNE THERAPIES
    Publication number: 20190321398
    Abstract: The present invention relates to tolerogenic mammalian dendritic cells (iDCs) and methods for the production of tolerogenic DCs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects. Enhanced tolerogenicity in a host can be useful for treating inflammatory and autoimmune related diseases, such as type 1 diabetes.
    Type: Application
    Filed: March 8, 2019
    Publication date: October 24, 2019
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Nick Giannoukakis, Massimo M. Trucco
  • Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies
    Patent number: 10272112
    Abstract: The present invention relates to tolerogenic mammalian dendritic cells (iDCs) and methods for the production of tolerogenic DCs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects. Enhanced tolerogenicity in a host can be useful for treating inflammatory and autoimmune related diseases, such as type 1 diabetes.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: April 30, 2019
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Nick Giannoukakis, Massimo M. Trucco
  • Particle formulations of all-trans retinoic acid and transforming growth factor beta for the treatment of type 1 diabetes mellitus
    Patent number: 10105334
    Abstract: Particle formulations are disclosed that include polymeric particles containing a small molecule drug and a high molecular weight therapeutic protein. Methods of making and using the particle formulations also are disclosed. These particle formulations are of use to treat an autoimmune disease, such as diabetes, or an inflammatory disease.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: October 23, 2018
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, Duquesne University
    Inventors: Nick Giannoukakis, Massimo M. Trucco, Wilson S. Meng
  • MICROSPHERE-BASED DELIVERY AND EX VIVO MANIPULATION OF DENDRITIC CELLS FOR AUTOIMMUNE THERAPIES
    Publication number: 20170360834
    Abstract: The present invention relates to tolerogenic mammalian dendritic cells (iDCs) and methods for the production of tolerogenic DCs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects. Enhanced tolerogenicity in a host can be useful for treating inflammatory and autoimmune related diseases, such as type 1 diabetes.
    Type: Application
    Filed: June 27, 2017
    Publication date: December 21, 2017
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Nick Giannoukakis, Massimo M. Trucco
  • Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies
    Patent number: 9724365
    Abstract: The present invention relates to tolerogenic mammalian dendritic cells (iDCs) and methods for the production of tolerogenic DCs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects. Enhanced tolerogenicity in a host can be useful for treating inflammatory and autoimmune related diseases, such as type 1 diabetes.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: August 8, 2017
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Nick Giannoukakis, Massimo M. Trucco
  • PARTICLE FORMULATIONS OF ALL-TRANS RETINOIC ACID AND TRANSFORMING GROWTH FACTOR BETA FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS
    Publication number: 20160338984
    Abstract: Particle formulations are disclosed that include polymeric particles containing a small molecule drug and a high molecular weight therapeutic protein. Methods of making and using the particle formulations also are disclosed. These particle formulations are of use to treat an autoimmune disease, such as diabetes, or an inflammatory disease.
    Type: Application
    Filed: January 16, 2015
    Publication date: November 24, 2016
    Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, Duquesne University
    Inventors: Nick Giannoukakis, Massimo M. Trucco, Wilson S. Meng
  • TOLEROGENIC DENDRITIC CELLS TO TREAT INFLAMMATORY BOWEL DISEASE
    Publication number: 20160230174
    Abstract: Methods are disclosed herein for treating or preventing an inflammatory bowel disease in a subject. These methods include administering to a subject an effective amount of tolerogenic dendritic cells, wherein the tolerogenic dendritic cells comprise at least one of an antisense compound specific for CD40, and antisense compound specific for CD80 and an antisense compound specific for CD86.
    Type: Application
    Filed: September 26, 2014
    Publication date: August 11, 2016
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Nick Giannoukakis, Massimo M. Trucco
  • MICROSPHERE-BASED DELIVERY AND EX VIVO MANIPULATION OF DENDRITIC CELLS FOR AUTOIMMUNE THERAPIES
    Publication number: 20150139965
    Abstract: The present invention relates to tolerogenic mammalian dendritic cells (iDCs) and methods for the production of tolerogenic DCs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects. Enhanced tolerogenicity in a host can be useful for treating inflammatory and autoimmune related diseases, such as type 1 diabetes.
    Type: Application
    Filed: November 18, 2014
    Publication date: May 21, 2015
    Inventors: Nick Giannoukakis, Massimo M. Trucco